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Background: Demyelination and failure of remyelination are core mechanisms in the pathogenesis of multiple
sclerosis (MS); the factor(s) modulating these processes are still mostly unknown. MicroRNA 572 (miR-572) is
deregulated in MS and is suggested to targets neural cell adhesion molecule (NCAM), a glycoprotein involved in
CNS reparative mechanisms. The aim of this study is to analyze miR-572 in patients with different clinical
phenotypes of MS.
Methods: qPCR quantification of miR-572 isolated from serum was performed in 16 primary progressive (PP), 15
secondary progressive (SP), 31 relapsing remitting (RR) MS patients and 15 sex-and age-matched healthy controls.
Results: miR-572 expression was reduced overall in MS patients (p < 0.05) compared to HC; this miRNA was significantly
upregulated in SPMS and in RRMS during disease relapse, whereas it was downregulated in PPMS and in quiescent
phases of RRMS. miR-572 expression correlated with EDSS scores (RSp = 0.491; p < 0.05) independently of the clinical
phenotype. The results suggest that this miRNA might be a tool that helps distinguishing between PPMS and SPMS and
between relapsing and remitting phases in RRMS.
Conclusions: Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination.
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Multiple Sclerosis (MS) is an inflammatory neurodegen-
erative disorder of the central nervous system (CNS) of
unknown etiology characterized by a high degree of het-
erogeneity with respect to clinical manifestations and re-
sponse to treatment. The pathological process common
to all forms of this disease is the inadequate repair of
myelin damage in CNS, a complex and yet mostly un-
clear process that becomes increasingly evident as MS
progresses [1]. Many reasons, including the inadequate
recruitment of oligodendrocytes precursor cells (OPC)
and an impairment in the processes leading OPC to dif-
ferentiate into oligodendrocytes, can hamper the remye-
lination process. The accumulation of myelin alterations
leads to axonal degeneration; this appears early in dis-
ease, but becomes prominent in the progressive form of* Correspondence: rmancuso@dongnocchi.it
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unless otherwise stated.MS [2,3], leading to further axonal and neuronal loss
and progression of disability.
Transient remyelination [4] and at least a partial res-
toration of conduction velocity [5] is seen in MS, pro-
cesses that can protect axons from injury and determine
the temporary remission of disease in RRMS [6]. The ef-
ficacy of the remyelination process varies widely in dif-
ferent patients and in different phases of the disease.
Thus, although remyelination is frequently more effi-
cient in the early stage of MS [4], extensive remyelina-
tion has been sometimes observed in chronic patients
[7], even if this phenomenon is usually rare or absent in
late chronic disease [8]. The degree of remyelination also
differs in the diverse clinical phenotypes of MS. Thus, a
more complete remyelination is known to occur in the
brain of primary progressive (PPMS) compared to sec-
ondary progressive (SPMS) patients [9], a finding that
might explain the relative preservation of cognitive func-
tion in PPMS patients [10].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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remyelination are still mostly unclear, the neural cell ad-
hesion molecule (NCAM or CD56) is suspected to play
an important role in this process, as this protein, that
belongs to the immunoglobulin super-family, is linked to
CNS reparative mechanism [11]. NCAM is an integral
membrane glycoprotein in neuronal and glial cells and it
promotes adhesion between cells through interacting
with homologous molecules on adjacent cells. Notably,
binding of NCAM to polysialic acid (PSA-NCAM) de-
creases cell adhesion, inducing structural remodeling in
brain during the development of the nervous system
[12] and contributing to the formation of axonal net-
works [13]. In the adult nervous system NCAM is
expressed in limited brain areas, where it is involved in
neuronal sprouting and synaptic remodeling [14], while
PSA-NCAM acts as a negative signal of myelination
[15]. Defective myelin compaction was observed in
NCAM deficient mice [16], and deletion of chromosome
coding sequence for NCAM in children has been associ-
ated with delayed myelination [17]. Finally, NCAM is
differentially expressed in active or chronic MS lesions
[18], and abnormal levels of soluble NCAM (NCAMs)
were suggested to be associated with the progression of
disability in MS [19,20].
Data stemming from a computational approach
(TargetScan) showed that NCAM is a possible target
for microRNA (miRNA) 572, a miRNA that was re-
cently observed to be deregulated in MS [21]. As is
the case with miRNAs, the result of the miR-572/
NCAM interaction would be the modulation of
NCAM activity, and this would correlate with the de-
gree of remyelination. We evaluated the levels of this
miRNA in serum of a group of MS patients with dif-
ferent clinical forms, analyzing possible correlations
with progression of disease and clinical characteristics.
Methods
Patients and samples collection
Thirty-one chronic progressive (16 primary progressive
–PPMS– and 15 secondary progressive –SPMS) and 31
relapsing remitting (RRMS) patients as well as 15 age-
and sex-matched healthy controls (HC) were enrolledTable 1 Demographic and clinical characteristics of the individua
PPMS SPMS St
N 16 15 16
Gender (M:F) 9:7 7:8 3:1
Age, yrs 52.8 ± 10.3 50.8 ± 8.0 42
Disease duration, yrs 13.4 ± 8.2 10.6 ± 9.9 10
EDSS 6.36 ± 1.63 6.64 ± 1.40 2.2
Mean value ± standard deviation are showed; MS: multiple sclerosis; PP: primary pro
Expanded Disability Status Scale; *Fisher’s exact test; #Anova test.for the study after signing an informed consent approved
by the Ethics Committee of the Don C. Gnocchi Foun-
dation-ONLUS in Milano, Italy. Among the RRMS pa-
tients, 15 were undergoing clinical relapse of the disease
whereas the other 16 were in a clinically stable phase
without areas of enhancement at the time of enrolment,
as demonstrated by magnetic resonance imaging (MRI)
with gadolinium.
All the patients were diagnosed according to the re-
vised McDonald criteria [22] and did not receive any
treatment for at least two months before the blood with-
drawal. RRMS patients in whom clinical relapse was ob-
served underwent blood collection before the first
glucocorticoid infusion. Demographic and clinical char-
acteristics of all the subjects enrolled are shown in
Table 1. Serum samples were obtained from whole blood
at the end of clotting time (60 minutes) by centrifuga-
tion (3400 g × 10 minutes).
miRNA target prediction
TargetScan (http://www.targetscan.org/), and MiRanda
(http://www.microrna.org/microrna/home.do) bioinfor-
matic tools were utilized to determine miRNA potential
target mRNAs.
miRNA isolation and cDNA retrotranscription
miRNA isolation from serum was performed with a col-
umn based kit (miRNeasy Mini kit, Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s specific proto-
col. Notably, as the yield of RNA from small volume
serum samples was below the limit of quantitation by
spectrophotometry, prior to miRNA extraction, 1 μg of
carrier RNA (MS2 RNA, Roche Life Science, Mannheim,
Germany) and 5 μl of non-human (C. elegans) synthetic
miR-39 (C.el.-miR-39) (5 nM) were added to 200 μl of
serum after denaturation with Qiazol Lysis Reagent. Total
RNA was eluted in 30 μl.
The inclusion of the synthetic miRNA was necessary
for adjusting for differences in efficiency of RNA recov-
ery between samples. Four μl of RNA was utilized for
retro-transcription reactions (in a final volume of 20 μl),
performed in triplicate using the universal cDNAls enrolled in the study
able RRMS Acute RRMS Controls p value
15 15
3 7:8 2:13 ns*
.8 ± 10.3 38.7 ± 8.4 38.7 ± 9.8 p < 0.01#
.6 ± 9.9 11.3 ± 8.0 / ns#
5 ± 2.11 3.73 ± 1.90 / p < 0.01#
gressive; SP: secondary progressive; RR: relapsing remitting; EDSS: Kurtzke
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sis kit, Exiqon Inc., Vedbaek, Denmark). Efficiency of
cDNA synthesis and absence of qPCR inhibitors were
monitored for all the samples by addition of the syn-
thetic control template (RNA spike-in, Exiqon Inc.). To
avoid variation due to sample differences and handling,
all the variables involved in the procedure were kept
consistent throughout the study.
miRNA selection and quantitative PCR assay
The study focused on a specific miRNA (miR-572) previ-
ously identified as being upregulated in plasma of MS
patients [21]. A specific LNA™-individual microRNAs
assay (Exiqon Inc.) was utilized to detect in sera the
miRNA target (hsa-miR-572; cat. 204696), reference
miRNAs, and the haemolysis control (hsa-miR-16; cat.
204409) according to the manufacturer’s instructions. A
set of 3 endogenous miRNAs was selected as candidate
reference genes to normalize the data: miR-103 (Exiqon,
cat. 204063), -191 (Exiqon, cat. 204306), −423 (Exiqon,
cat. 204593). A synthetic C.el. miR-39 (Exiqon, cat.
203952) was also used to normalize the results.
Briefly, qPCR amplification was performed on real
time PCR system (Step One, Applied Biosystem, Foster
City, CA) in 10 μl of reaction mix containing SYBR
GREEN master mix (Exiqon Inc.), specific primer set
for each miRNA and 4 μl of cDNA. Each cDNA tem-
plate was tested in triplicate by qPCR. Negative controls,
without rt-template controls, and no-template controls
were included in each session. An additional step in the
qPCR analysis was performed to evaluate the specificity
of the amplification products by generating a melting
curve for each reaction.
Data processing and statistical analysis
Manual baseline and threshold were set manually on the
instrument for the evaluation of row Cq value for each
sample. Because of the scarcity of miRNA in serum, Cq =
38 was set as the cut-off.
The NormFinder algorithm was used to calculate the
expression stabilities of the candidate reference genes.
NormFinder calculates the stabilities of candidate refer-
ence genes based on the intra- and inter-group varia-
tions. A lower stability value indicates a more stably
expressed gene [23].
Relative quantification was determined by the com-
parative delta-Cq method using the more stable refer-
ence miRNA (ref ) indicated by NormFinder for median
normalization procedure: (Raw Cq value - [(ref miRNA
average Cq of the given sample) - (ref miRNA median
Cq value)]; fold expression levels (2-ΔΔCq) were calcu-
lated as described [24]; fold change < 0.5 was indicative
of down-regulation and > 2 of up-regulation. Absence of
qPCR inhibition for haemolysis was verified monitoringthe stability of Cq of miR-16, commonly found in red
blood cells.
Statistical analyses were accomplished using commer-
cial software (MedCalc®, version 11.5.0.0).
Demographic and clinical quantitative data, reported
as mean and standard deviation, were analyzed by one-
way analysis of variance (ANOVA). The others quantita-
tive variable, not normally distributed, are expressed as
median and 95% confidence interval (CI). Logarithmic
transformation was applied to miR-572 relative expres-
sion fold, and Kruskal-Wallis was used to compare value
among groups, whereas Mann Whitney test was used to
determine the significance between two groups. Spear-
man’s rank correlation coefficient was used in the correl-
ation analysis between miR-572 and clinical variables. p
values < 0.05 were considered statistically significant. Re-
ceiver operating characteristics analysis (ROC) and area
under curve (AUC) were used to evaluate the potential
of miRNA as biomarker (see Additional file 1).
Results
Selection of candidate reference genes
C.el miR-39 was selected for normalization because
NormFinder ranked it as the most stably expressed gene,
followed by miR-103, miR-423, and miR-191.
Moreover, normalization with two other miRNAs
(miR-103, miR-423) was performed to confirm the ana-
lysis obtained with C.el miR-39.
miR-572 expression levels in MS patients and in HC
The expression levels of circulating miR-572 were evalu-
ated in MS patients with different clinical disease pheno-
types as well as in HC. Demographic and clinical details
showed that disease duration was comparable for all
groups, although patients’ age was significantly higher in
progressive than in RRMS (Table 1).
Results showed that the serum concentration of miR-572
was significantly down regulated in the overall group of MS
patients (median fold: 0.01; 95% CI: 0.01-0.05) compared to
HC (0.98; 0.26-2.63, p = 0.0025) (Figure 1, Panel A).
miR-572 expression levels in MS patients with different
disease phenotype
Notably, a wide variation of miR-572 expression levels
was observed when miR-572 serum concentration was
compared in MS patients with different patterns of dis-
ease. Thus, the lowest serum concentration of this
miRNA was detected in PPMS (0.01; 0.01-0.012) and in
RRMS patients during the remitting phase of disease
(0.01; 0.01-0.01); the values observed in these cases were
significantly lower than those seen in HC (p < 0.001 in
both cases). Conversely, serum concentration of miR-
572 was significantly increased in SPMS (3.4; 0.01-
212.94) compared to PPMS patients (p = 0.01), and in
Figure 1 miR-572 expression level in serum of MS patients and controls. miR-572 relative expression fold change (ref: C. el. miR-39) in serum of
MS patients and healthy controls (HC) (panel A) and of MS patients with different disease phenotypes, using as reference C. el miR-39 (panel B),
miR-103 (panel C) and miR-423 (panel D). Analyses reported in panel C and D were performed on a subgroup of subjects. PPMS = primary
progressive MS; SPMS = secondary progressive MS; RRMS = relapsing-remitting MS. Bars represent the median values; statistical significance
is shown.
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1.03) in comparison to those RRMS patients evaluated
during remission (p < 0.001) (Figure 1, Panel B). In
Figure 1, panels C represents miR-572 expression after
normalization with miR-103; results in panel D are
normalized with miR-423.
Correlations between miR-572 serum concentrations and
clinical parameters
The Kurtzke Expanded Disability Status Scale (EDSS) is
a widely accepted method of quantifying disability in
MS; possible correlations between EDSS scores and
miR-572 serum concentrations were analyzed. Consider-
ing the overall MS population, a significant positive cor-
relation independently from the clinical phenotype wasobserved between relative expression of miR-572 in
serum and EDSS disability score (Rs = 0.477; p = 0.018)
(Figure 2); in contrast with these results, disease duration
was not associated with miR-572 serum concentration.
Discussion
Circulating miRNAs have emerged as potential bio-
markers for several human diseases including MS
[25,26]. In the present study the expression levels of
miR-572 were evaluated in serum of MS patients with
different patterns of disease. We focused on this mol-
ecule because of data indicating that circulating levels of
miR-572 are increased in MS patients [21] and because
a putative target for miR-572 is the neuronal cell adhe-
sion molecule (NCAM), a protein involved in the
Figure 2 Correlation between miR-572 and disability in MS patients.
Correlation between miR-572 relative expression fold change in serum
and Kurtzke Expanded Disability Status Scale (EDSS) in MS patients.
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cently also suggested to play a role in neurodegenerative
diseases. In fact many evidences showed the influence of
NCAM in neurite outgrowth [28], synaptic plasticity
[29] and CNS repair and remyelination [30].
Results showed that miR-572 was down-regulated in
the MS patients compared to HC subjects, a phenomenon
already evidenced in previous analyses on other miRNAs
[26,31]; interestingly, a modulation of miR-572 was ob-
served upon clustering of MS patients in accordance with
clinical course. Thus, comparisons between groups
showed that serum levels of miR-572 were markedly differ-
ent when the primary and secondary forms of progressive
MS were compared, with significant increase in SPMS and
significant decrease in PPMS. Similarly, in RRMS patients
a significant increase of serum concentrations of miR-572
was observed in relapsing compared to remitting patients.
It is known that a major challenge for the analysis of
circulatory miRNA is data normalization, a crucial point
for an objective evaluation of their expression level and
to avoid the introduction of systematic bias in the ana-
lysis. The strategy we adopted was to use a synthetic
spike-in oligonucleotide, as reported by several other pa-
pers [32,33]. Thus, C. el miR-39 was selected as refer-
ence because indicated as the best candidate by
Normfinder software. To further confirm our results
two other miRNA (miR-103, miR-423) were used singu-
larly to normalize the data; the three methods led to the
same results.
Plasma levels of miR-572 were previously reported to
be increased in MS patients [21]. The discrepancy be-
tween these and our results can be explained consider-
ing that the data reported by Siegel et al. stem from
analyses performed in a very small group (n = 4) of MS
patients that were not clinically classified. Moreover, sig-
nificant variation in specificity among different qPCR
platform/methods is a well known problem as lessabundant miRNAs can escape detection with technolo-
gies such as microarray, cloning and hybridization [34].
Thus, the choice of the method used (qPCR array vs. in-
dividual qPCR with LNA™-primers), or of different bio-
logical samples (serum vs. plasma) as well as the clinical
course of analyzed patients can explain these discrepancies.
Different studies have investigated whether serum con-
centration of soluble NCAM (NCAMs) could be used as
a biomarker in human pathology [35]. Particularly, in
MS the low levels of NCAMs detected in the cerebro-
spinal fluid (CSF) suggest that this molecule could con-
tribute to the decreased CNS repair observed in this
disease [36,37]. Notably, recent data showed the pres-
ence of a negative correlation between EDSS scores and
CSF NCAMs levels, and demonstrated that the concen-
tration of NCAMs decreases with disease progression
[19]. On the contrary, increasing CSF NCAMs levels are
observed in RRMS patients after treatment of the acute
phase with corticosteroids [36], paralleling the progres-
sive clinical improvement seen after the cessation of re-
lapses, and indicating a possible relation with myelin
repair mechanism.
Understanding the mechanism(s) responsible for the
modulation of NCAM thus could shed light on the
pathogenesis of MS and, possibly, open novel thera-
peutic avenues for this disease. In the attempt to clarify
this issue we analyzed serum levels of miR-572, a
miRNA that is suggested by computational approaches
to bind NCAM and, thus, regulates its activity. Results
herein are the first in which circulating levels of miR-
572 are analyzed in a large group of MS patients sub-
divided according to the disease course. Because an
increase of miRNA is mostly associated with expres-
sion and activity reduction of the target protein [38],
the correlation between serum levels of miR-572 and
MS clinical phenotypes allows the speculation that the
observed changes in miR-572 may result in different
degrees of myelin repair activity. This hypothesis is
supported by the fact that the concentration of miR-
572 was significantly reduced (hence NCAM activity
was likely significantly increased) in PPMS patients, in
whom a more complete remyelination is known to
occur [9]. Further support to this possibility stems
from the observation that initiation of steroids in
RRMS patients with disease relapses resulted in the
reduction of serum concentration of miR-572 (our
data) and a parallel increase of NCAMs in CSF [36].
Finally, a positive correlation was observed between
serum miR-572 levels and disability score in MS pa-
tients; these results are specular to the recently re-
ported inverse correlation detected in MS between
NCAMs in CSF and EDSS scores [19]. An important
weakness of the study is the limited number of ana-
lyzed patients; this could have influenced the results.
Mancuso et al. Journal of Translational Medicine  (2015) 13:148 Page 6 of 7Further analyses with a larger cohort will be necessary
to confirm these preliminary data and to validate
experimentally the miR-572/NCAM target interaction
and modulation.Conclusions
Our results suggest that miR-572 could be one of the
regulatory factors involved in the remyelination process
and raise the possibility that the changes in miR-572
expression seen in MS patients with different patterns of
disease may play a role in such process and could be
used as a biomarker.
Additional file
Additional file 1: Figure S1. Receiver operating characteristic analysis
of miR-572 for discriminating between MS and HC. To evaluate the
potential of miRNA as biomarkers, receiver operating characteristics analysis
(ROC) and area under curve (AUC) were performed. Results showed that
serum levels of miR-572 have a predictive value in distinguishing MS from
HC (AUC: 0.741; 95% CI: 0.623-0.834; p= 0.0003) and PPMS from SPMS
(AUC: 0.765; 95% CI: 0.544-0.915; p=0.0067). Moreover serum miR-572
concentrations could clearly distinguish between acute and stable
disease in RRMS patients (AUC 0.848; 95% CI: 0.674-0.951; p<0.0001).
ROC curves of serum concentration of miR-572 in MS patients and HC
(panel A), in PPMS compared to SPMS patients (panel B) and in relapsing
compared to remitting MS (panel C). AUC: area under curve; CI: confidence
interval. For Methods see main text.
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